Value-Engineered Translation for Regenerative Medicine: Meeting the Needs of Health Systems

• Author(s) / Creator(s)

  • McCabe, Christopher
  • Bubela, Tania

• Despite high expectations of economic returns, large investments in regenerative medicine technology have yet to materialize, partly due to a lack of proven business and investment models, regulatory hurdles, and a greater focus on cost-effectiveness for reimbursement decisions by payors. Adoption of new economic modeling methods will better link investment decisions to value-based criteria of health systems.

• Date created

  2014-10-29

• Subjects / Keywords

  • TECHNOLOGIES
  • EXPECTED VALUE
  • REIMBURSEMENT
  • DRUGS
  • UNCERTAINTY
  • INFORMATION
  • DECISION-MAKING
  • THERAPIES
  • STEM-CELL RESEARCH
  • COST-EFFECTIVENESS

• Type of Item

  Research Material

• DOI

  https://doi.org/10.7939/R33T9DC7R

• License

  This is a copy of an article published in Stem Cells and Development © 2013 copyright Mary Ann Liebert, Inc.; Stem Cells and Development is available online at: http://online.liebertpub.com.